<div id="readability-page-1"><div><ul> <li>In December 2025, Halozyme Therapeutics announced a global collaboration and exclusive license agreement granting Takeda access to its ENHANZE drug delivery technology, including rights to use recombinant human hyaluronidase PH20 with vedolizumab for inflammatory bowel disease, in exchange for an upfront payment, potential milestones, and low- to mid-single-digit royalties.</li> <li>This deal extends ENHANZE into a widely used biologic therapy for Crohn’s disease and ulcerative colitis, potentially broadening Halozyme’s royalty base across a large global IBD patient population.</li> <li>We’ll now examine how expanding ENHANZE onto vedolizumab with Takeda could influence Halozyme’s investment narrative and future royalty profile.</li> </ul><p>Uncover the next big thing with financially sound penny stocks that balance risk and reward.</p><h2>Halozyme Therapeutics Investment Narrative Recap</h2><p>To own Halozyme, you need to believe in the resilience of its ENHANZE royalty model and its ability to keep adding meaningful partners across large indications. The Takeda vedolizumab deal supports this thesis by plugging ENHANZE into a major IBD therapy, but it does not change that the key near term swing factor is performance and contract stability across Halozyme’s largest existing royalty streams, nor the ongoing risk from regulatory and reimbursement pressure on biologic pricing.</p> <p>The Takeda collaboration fits alongside Halozyme’s broader push to widen ENHANZE adoption, following the late 2025 non exclusive deal with Merus for petosemtamab in oncology. Together, these agreements highlight how incremental ENHANZE partnerships can add optionality to future royalties while the company continues to post growing revenue and earnings, backed by raised 2025 guidance and strong recent profitability, even as it manages concentration risk in a handful of anchor products.</p> <p>Yet, despite the appeal of ENHANZE’s expanding partner list, investors still need to understand the revenue concentration risk if...</p> <p>Read the full narrative on Halozyme Therapeutics (it's free!)</p><p>Halozyme Therapeutics' narrative projects $2.0 billion revenue and $1.1 billion earnings by 2028. This requires 18.7% yearly revenue growth and a roughly $542.7 million earnings increase from $557.3 million today.</p><p>Uncover how Halozyme Therapeutics' forecasts yield a $76.00 fair value, a 7% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9e8d4ff6-f2fa-4f84-9e15-57eccd52c112/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9e8d4ff6-f2fa-4f84-9e15-57eccd52c112/chart/quote-price"/><figcaption>HALO 1-Year Stock Price Chart</figcaption></figure> <p>Eight fair value estimates from the Simply Wall St Community span roughly US$76 to US$200 per share, reflecting very different expectations for Halozyme’s potential. You can weigh those views against the dependence on a concentrated set of major ENHANZE partnerships and consider how that might influence Halozyme’s future royalty resilience and overall performance.</p><p>Explore 8 other fair value estimates on Halozyme Therapeutics - why the stock might be worth just $76.00!</p><h2>Build Your Own Halozyme Therapeutics Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Halozyme Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.</li></ul><h2>Searching For A Fresh Perspective?</h2><p>Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:</p><ul><li>Find companies with promising cash flow potential yet trading below their fair value.</li><li>Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li><li>AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

SBIO

IBBQ

HALO

<p>Halozyme Therapeutics has entered a global collaboration with Takeda, granting access to its ENHANZE drug delivery technology for vedolizumab, aimed at treating inflammatory bowel disease. This deal could enhance Halozyme's royalty base significantly. While the partnership supports Halozyme's investment narrative, concerns remain regarding revenue concentration risks and regulatory pressures. The company projects $2 billion in revenue by 2028, with a fair value estimate of $76 per share, reflecting varying investor expectations. Despite the potential, investors should consider the risks associated with reliance on major partnerships.</p>

Simplywall

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Takeda Pharmaceutical Company

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Halozyme Therap

Is Takeda ENHANZE Deal on Vedolizumab Reshaping the Investment Case for Halozyme Therapeutics (HALO)?